DrugDashboards

Market view

bimekizumab · Injection, Solution

10 marketed package NDCs · 2 active manufacturers

Most dispensed: 160 mg/mL · Injection, Solution · #1 syringe, glass/carton / 1 ml in 1 syringe, glass · 160 mg/mL · Injection, Solution · #2 syringe, glass/carton / 1 ml in 1 syringe, glass · 320 mg/2mL · Injection, Solution · #1 syringe, glass/carton / 2 ml in 1 syringe, glass

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $8025.55 per mL over the past year. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

Price range and competition

RSS: changes for this drug

Every company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.

$0$5000.00$10000.00Sep 2025Sep 202602companies actively selling

Latest · Sep 2026 — typical price $8025.55 · middle half $8020.80$8030.31 · full range $8016.04$8035.07 · 2 products · 2 companies

middle half of companies’ pricestypical (median) pricecompanies actively selling (bottom lane)Priced per mLSource: CMS NADAC
ⓘ How this was built
Data sources
  • CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
  • CMS Federal Upper Limit files (weighted AMP)
  • FDA NDC Directory (openFDA) — maker roster
Method

Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

What changed in the last 90 days

Every detected change for bimekizumab, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.

  • bimekizumabAug 26, 2026
    Mfr exited
    UCB Pharma S.A. · bimekizumab
  • BimzelxAug 19, 2026
    Price down
    NADAC $8021.619 → $8016.03643 per unit (-0.07%)
  • BimzelxAug 19, 2026
    Price up
    NADAC $8017.368 → $8035.07333 per unit (+0.22%)
  • BimzelxJul 22, 2026
    Price down
    NADAC $8023.83667 → $8021.619 per unit (-0.03%)
  • BimzelxJul 22, 2026
    Price down
    NADAC $8046.42677 → $8017.368 per unit (-0.36%)

Common questions

Is Bimekizumab in shortage right now?
No. FDA does not currently list Bimekizumab in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
Who makes Bimekizumab?
3 companies have marketed Bimekizumab in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
What does Bimekizumab cost?
The typical pharmacy pays about $8,025.55 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.

All marketed products

Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.